Pacific Biosciences of California, INC Schedule 13G passive stakes

ARK Investment Management LLC and Catherine D. Wood have filed an amendment confirming their joint beneficial ownership of 9.59% of Pacific Biosciences of California, Inc. common stock as of June 30, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Pacific Biosciences of California Inc following an internal realignment.

ARK Investment Management LLC and Catherine D. Wood have jointly filed an Amendment No. 6 on Schedule 13G, disclosing a combined beneficial ownership of 12.34% in Pacific Biosciences of California, Inc.

Madrone Capital Partners and related entities, including Gregory Penner, filed an amended Schedule 13G disclosing their beneficial ownership in Pacific Biosciences of California, Inc.

ARK Investment Management LLC and Catherine D. Wood have disclosed a 10.30% beneficial ownership stake in Pacific Biosciences of California, Inc.

Madrone Capital Partners and related entities disclose increased beneficial ownership in Pacific Biosciences of California, Inc., reaching 6.8% of common stock.

Edmond de Rothschild Asset Management entities and Edmond de Rothschild Fund have disclosed beneficial ownership of up to 4.5% of Pacific Biosciences of California, Inc. common stock as of June 30, 2025.

The Vanguard Group has filed an Amendment No. 3 to its Schedule 13G, disclosing a 5.46% beneficial ownership stake in Pacific Biosciences of California Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.7% beneficial ownership stake in Pacific Biosciences of California, Inc. as of March 31, 2025.

Millennium Management LLC and its affiliates have significantly reduced their beneficial ownership in Pacific Biosciences of California, Inc. to 0.7% of common stock, triggering an amendment to their Schedule 13G filing.